GlassScriptPhysician profile
Crystal Shereen Denlinger
NPI 1063626190
$33,167.74
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $15K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $8,520.16 | 2019-2020 | |
| Taiho Oncology, INC. | $7,841.45 | 2020 | |
| Astellas Pharma US INC | $6,799.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $4,562.50 | 2020 | |
| Lilly USA, LLC | $4,169.74 | 2019 | |
| Merck Sharp & Dohme LLC | $1,250.00 | 2020 | |
| Sirtex Medical INC | $24.33 | 2019 |
8 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Denlinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.